| Old Articles: <Older 48381-48390 Newer> |
|---|
 |
The Motley Fool
April 29, 2011
David Williamson |
Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes.   |
The Motley Fool
April 29, 2011
Rich Smith |
Motorola-a-Mo-Mo But how much farther can it go-go? |
The Motley Fool
April 29, 2011
Shubh Datta |
Starbucks Is Looking Very Bullish Starbucks attempts to strengthen its position in emerging markets. |
The Motley Fool
April 29, 2011
Brian Orelli |
Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib. |
The Motley Fool
April 29, 2011
Brian Orelli |
Oral Multiple Sclerosis Drugs Heat Up Watch out Novartis and Gilenya. |
The Motley Fool
April 29, 2011
Christopher Barker |
This Gold Miner Will Reward Your Patience Agnico-Eagle Mines remains poised to outperform gold's ongoing advance. |
The Motley Fool
April 29, 2011
Tim Beyers |
This Just In: NetGear Killed It at CES First-quarter results blow away Wall Street estimates. |
The Motley Fool
April 29, 2011
David Lee Smith |
Big Oil Is Booming The likes of ExxonMobil, Royal Dutch Shell, and Occidental love these macro trends. |
The Motley Fool
April 29, 2011 |
Who Will Lead Sony Into the Future? One name is being floated around. |
The Motley Fool
April 29, 2011
David Meier |
Why You Shouldn't Invest in These Cash Kings Here's when you need to be careful. |
| <Older 48381-48390 Newer> Return to current articles. |
